Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ahmad N, Iskandarani"'
Autor:
Kirti S. Prabhu, Kodappully Sivaraman Siveen, Shilpa Kuttikrishnan, Ahmad N. Iskandarani, Abdul Q. Khan, Maysaloun Merhi, Halima E. Omri, Said Dermime, Tamam El-Elimat, Nicholas H. Oberlies, Feras Q. Alali, Shahab Uddin
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Therapeutic agents used in the treatment of cancer are known to develop resistance against cancer cells. Hence, there is a continuing need to investigate novel agents for the treatment and management of cancer. Antitumor activity of greensporone C (G
Externí odkaz:
https://doaj.org/article/a079312082f34a63875ab8e586087691
Autor:
Rabab M. El Eit, Ahmad N. Iskandarani, Jessica L. Saliba, Mark N. Jabbour, Rami A. Mahfouz, Nizar M.A. Bitar, Hanadi R. El Ayoubi, Ghazi S. Zaatari, Francois-Xavier Mahon, Hugues B. De Thé, Ali A. Bazarbachi, Rihab R. Nasr
Publikováno v:
International Journal of Cancer. 134:988-996
Imatinib is the standard of care in chronic meloid leukemia (CML) therapy. However, imatinib is not curative since most patients who discontinue therapy relapse indicating that leukemia initiating cells (LIC) are resistant. Interferon alpha (IFN) ind
Autor:
Rihab R, Nasr, Raed A, Hmadi, Rabab M, El-Eit, Ahmad N, Iskandarani, Mark N, Jabbour, Ghazi S, Zaatari, Francois-Xavier, Mahon, Claudio C P, Pisano, Nadine D, Darwiche
Publikováno v:
International journal of cancer. 137(3)
The tyrosine kinase inhibitor, imatinib, is the first line of treatment for chronic myeloid leukemia (CML) patients. Unfortunately, patients develop resistance and relapse due to bcr-abl point mutations and the persistence of leukemia initiating cell